

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

SYNTHESIS AND ADENOSINE RECEPTOR AFFINITY AND POTENCY OF 8-ALKYNYL DERIVATIVES OF ADENOSINE

C. Lambertucci^a; S. Costanzi^a; S. Vittori^a; R. Volpini^a; G. Cristalli^a

^a Dipartimento di Scienze Chimiche, University of Camerino, Camerino, Italy

Online publication date: 31 March 2001

To cite this Article Lambertucci, C. , Costanzi, S. , Vittori, S. , Volpini, R. and Cristalli, G.(2001) 'SYNTHESIS AND ADENOSINE RECEPTOR AFFINITY AND POTENCY OF 8-ALKYNYL DERIVATIVES OF ADENOSINE', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 1153 – 1157

To link to this Article: DOI: 10.1081/NCN-100002509

URL: <http://dx.doi.org/10.1081/NCN-100002509>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ADENOSINE RECEPTOR AFFINITY AND POTENCY OF 8-ALKYNYL DERIVATIVES OF ADENOSINE

C. Lambertucci, S. Costanzi, S. Vittori, R. Volpini, and G. Cristalli*

Dipartimento di Scienze Chimiche, University of Camerino,
I-62032 Camerino, Italy

ABSTRACT

Adenosine derivatives bearing different (ar)alkynyl chains at the 8-position were synthesized and tested at human adenosine receptors. Binding studies showed that all compounds possess affinity for the A₃ subtype in the high nM range. Moreover, guanosine 5'-O-(3-[³⁵S]thio)triphosphate binding assay indicated that the 8-alkynyl adenosines behaved as antagonists of NECA at A₃ receptors.

Adenosine (Ado) is a signalling molecule that mediates diverse biological effects via interaction with four different cell surface receptors termed A₁, A_{2A}, A_{2B} and A₃ (1). In recent years we demonstrated that C-2-substituted 5'-N-ethylcarboxamidoadenosine (NECA) are potent and selective ligands for adenosine receptor subtypes (2,3). In particular compounds bearing a hexynyl, phenylethynyl, and phenylhydroxypropynyl chains at the 2-position of NECA possess high affinity for A₃ receptors combined, in some cases, with good selectivity (4). In order to investigate the role of the carboxamido group at the 5'-position and to simplify the structure of these molecules, we synthesized adenosine derivatives bearing the above mentioned alkynyl chains at the C-2-position (5). Binding studies at human adenosine receptors showed that the 2-alkynyl derivatives of Ado possess good and comparable affinity at all receptor subtype in comparison to the corresponding NECA derivatives (5). These findings prompted us at investigating the effect of such substituent in a different position of adenosine; to this purpose we

*Corresponding author.

synthesized adenosine derivatives bearing in C-8-position the three above mentioned alkynyl chains. All the synthesized compounds were evaluated at human recombinant adenosine receptors, stably transfected into Chinese Hamster Ovary (CHO) cells, utilizing radioligand bindings (A_1 , A_{2A} , A_3) or adenylyl cyclase activity assays (A_{2B}) (6). Preliminary results showed that in all cases the introduction of an alkynyl chain at the C-8 position of Ado is detrimental for the affinity and potency at A_1 , A_{2A} , and A_{2B} receptors, while is more tolerated by the A_3 receptor (K_i A_3 in the high nM range).

Furthermore, the intrinsic activity of the C-8-alkynylAdos were determined in guanosine 5'-O-(3-[35 S]thio)triphosphate ([35 S]GTP γ S) binding assay in membranes of CHO cells which express the human A_3 receptor subtype. NECA (1 μ M) was used as reference full agonist and its stimulation of [35 S]GTP γ S binding to the G protein was set to 100% (7). Surprisingly, the C-8-alkynylAdos behaved as A_3 adenosine antagonists. In fact they did not stimulate basal GTP γ S binding, but inhibited to various extent NECA-stimulated binding.


CHEMISTRY

The synthesis of 8-substituted adenosines (**2a–d**) was accomplished starting from commercial 8-bromoadenosine (8-BrAdo, **1**). Substitution of the bromine in the 8-position of **1** with the three different alkynyl chains (commercially available hexyne, phenylethyne or phenylhydroxypropyne) was carried out by a modification of the palladium catalyzed cross-coupling reaction (2) described in the general method (Scheme 1). Reaction of **1** with phenylhydroxypropyne did not give the corresponding 8-phenylhydroxypropyne (**2d**) but a product deriving from a tautomeric rearrangement on the side chain (**2c**). The structure of (*Z*)-8-(3-keto-3-phenyl-1-propen-1-yl)-9-(β -D-ribofuranosyl)adenine (**2c**) was confirmed by 1 H NMR and 13 C NMR. In fact the 1 H NMR displayed two doublets of the (*Z*) double bond protons at δ 7.87 and 8.22 with a coupling constant of 15.2 Hz, while the 13 C NMR showed a carbonyl group signal at 188.4 ppm. The same reaction, performed on the acetylated 8-bromoAdo (**3**) (8) as reported in Scheme 1, was successful and gave compound **4** which was deprotected with methanolic ammonia to obtain the desired 8-phenylhydroxy propynylAdo (**2d**), although in very low yield.

EXPERIMENTAL

Melting points were determined with a Büchi apparatus and are uncorrected. 1 H and 13 C NMR spectra were obtained with Varian VXR 300 MHz spectrometer; δ in ppm, *J* in Hz. All exchangeable protons were confirmed by addition of D₂O. TLC were carried out on pre-coated TLC plates with silica gel 60 F-254 (Merck). For column chromatography, silica gel 60 (Merck) was used. Elemental analyses





Scheme 1.

were determined on Carlo Erba model 1106 analyser and are within $\pm 0.4\%$ of theoretical values.

General method for the synthesis of 8-(ar)alkynyladenosines 2a–c, and 4. To a solution of **1** or **3** (0.51 mmol) in dry DMF (15 mL), and Et₃N (2.3 mL) under an atmosphere of N₂ were added bis(triphenylphosphine)palladium dichloride (8.1 mg, 0.012 mmol) and CuI (0.51 mg, 0.003 mmol). The appropriate terminal alkyne (3.1 mmol) was added and the reaction mixture was stirred under an atmosphere of N₂ at room temperature for the time reported for each compound. The solvent was removed *in vacuo* and the residue was chromatographed on a silica gel column or TLC plates eluting with a suitable mixture of solvents to give the desired derivatives **2a–c**, or **4** as amorphous solids.

8-(1-Hexyn-1-yl)-9-(β-D-ribofuranosyl)adenine (2a). The reaction of **1** with 1-hexyne for 16 h, followed by chromatography on a silica gel column eluted with CHCl₃-MeOH (92:8), gave **2a** (138 mg; 69%); ¹H NMR (Me₂SO-*d*₆) δ 0.94 (t, *J* = 7.1 Hz, 3H, CH₃), 1.53 (m, 4H, (CH₂)₂-CH₃), 2.59 (t, *J* = 6.7 Hz, 2H,



CH₂-C≡C), 3.62 (m, 2H, CH₂-5'), 3.99 (m, 1H, H-4'), 4.22 (m, 1H, H-3'), 5.03 (m, 1H, H-2'), 5.95 (d, *J* = 6.9 Hz, 1H, H-1'), 7.50 (bs, 2H, NH₂), 8.15 (s, 1H, H-8). Anal. calcd. for C₁₆H₂₁N₅O₄ (347.37): C 55.32, H 6.09, N 20.16; found: C 55.25, H 6.00, N 20.28.

8-(Phenylethyn-1-yl)-9-(β-D-ribofuranosyl)adenine (2b). The reaction of **1** with phenylethyne for 48 h, followed by chromatography on a silica gel column eluted with CHCl₃-MeOH (92:8), gave **2b** (153 mg; 72%); ¹H NMR (Me₂SO-*d*₆) δ 3.64 (m, 2H, CH₂-5'), 4.03 (m, 1H, H-4'), 4.23 (m, 1H, H-3'), 5.04 (m, 1H, H-2'), 6.07 (d, *J* = 6.7 Hz, 1H, H-1'), 7.55 (m, 3H, H-Ph), 7.66 (m, 4H, H-Ph and NH₂), 8.20 (s, 1H, H-8). Anal. calcd. for C₁₈H₁₇N₅O₄ (367.36): C 58.85, H 4.66, N 19.06; found: C 55.50, H 4.56, N 19.16.

(Z)-8-(3-Keto-3-phenyl-1-propen-1-yl)-9-(β-D-ribofuranosyl)adenine (2c). The reaction of **1** with 3-hydroxy-3-phenyl-1-propyne for 4 days, followed by chromatography on a silica gel TLC plate eluted with CHCl₃-MeOH (85:15), gave **2c** (92 mg; 45%); ¹H NMR (Me₂SO-*d*₆) δ 3.64 (m, 2H, CH₂-5'), 4.04 (m, 1H, H-4'), 4.20 (m, 1H, H-3'), 4.89 (m, 1H, H-2'), 6.10 (d, *J* = 6.6 Hz, 1H, H-1'), 7.69 (m, 5H, H-Ph and NH₂), 7.87 (d, *J* = 15.2 Hz, 1H, CH), 8.08 (d, *J* = 7.0, 2-H, H-Ph), 8.18 (s, 1H, H-2). 8.22 (d, *J* = 15.2 Hz, 1H, CH), ¹³C NMR (Me₂SO-*d*₆) δ 61.9 (C-5'), 70.6 (C-3'), 72.3 (C-2'), 86.6 (C-4'), 87.8 (C-1'), 119.5 (C-5), 128.0 (C = C), 128.2 (C-Ph), 128.4 (C-Ph), 128.6 (C-Ph), 129.1 (C-Ph), 133.7 (C = C), 136.9 (C-Ph), 145.6 (C-8), 150.0 (C-4), 153.1 (C-2), 156.2 (C-6), 188.4 (CO). Anal. calcd. for C₁₉H₁₉N₅O₅ (397.38): C 57.43, H 4.82, N 17.62; found: C 57.38, H 4.77, N 17.82.

8-(3-Hydroxy-3-phenyl-1-propyn-1-yl)-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)adenine (4). The reaction of **3** (8) with 3-hydroxy-3-phenyl-1-propyne for 3 days, followed by chromatography on a silica gel column eluted with CHCl₃-MeOH (96:4), gave **4** (34 mg; 13%); ¹H NMR (Me₂SO-*d*₆) δ 1.96 (s, 3H, COCH₃), 2.04 (s, 3H, COCH₃), 2.12 (s, 3H, COCH₃), 4.17 (m, 1H, CH₂-5'), 4.40 (m, 2H, CH₂-5' and H-4'), 5.75 (m, 2H, H-1' and H-3'), 6.17 (m, 2H, H-2' and CH-OH), 7.43 (m, 3H, H-Ph), 7.59 (m, 4H, H-Ph and NH₂), 8.22 (s, 1H, H-2). Anal. calcd. for C₂₅H₂₅N₅O₈ (523.49): C 57.36, H 4.81, N 13.38; found: C 57.33, H 4.75, N 13.52.

8-(3-Hydroxy-3-phenyl-1-propyn-1-yl)-9-(β-D-ribofuranosyl)adenine (2d). A mixture of **4** (0.07 mmol) and methanolic ammonia (3 mL) was stirred at room temperature for 30 min. The reaction mixture was evaporated and the residue was chromatographed on a silica gel TLC plate eluted with CHCl₃-MeOH (80:20) to give **2d** (6 mg; 23%); ¹H NMR (Me₂SO-*d*₆) δ 3.61 (m, 2H, CH₂-5'), 3.98 (m, 1H, H-4'), 4.21 (m, 1H, H-3'), 5.03 (m, 1H, H-2'), 5.77 (d, *J* = 5.7 Hz, 1H, CH-OH), 5.99 (d, *J* = 6.7 Hz, 1H, H-1'), 7.44 (m, 2H, H-Ph), 7.62 (m, 5H,



8-ALKYNYL DERIVATIVES OF ADENOSINE

1157

H-Ph and NH₂), 8.17 (s, 1H, H-2). Anal. calcd. for C₁₉H₁₉N₅O₅ (397.38): C 57.43, H 4.82, N 17.62; found: C 57.23, H 4.79, N 17.82.

ACKNOWLEDGMENT

Supported by EC Contract No BMH4-98-3474 and by a grant from the University of Camerino (Fondo di Ricerca di Ateneo).

REFERENCES

1. Ralevic, V.; Burnstock, G. *Pharmacol. Rev.* **1998**, *50*, 413–492.
2. Cristalli, G.; Volpini, R.; Vittori, S.; Camaioni, E.; Monopoli, A.; Conti, A.; Dionisotti, S.; Zocchi, C.; Ongini, E. *J. Med. Chem.* **1994**, *37*, 1720–1726.
3. Cristalli, G.; Camaioni, E.; Vittori, S.; Volpini, R.; Borea, P. A.; Conti, A.; Dionisotti, S.; Ongini, E.; Monopoli, A. *J. Med. Chem.* **1995**, *38*, 1462–1472.
4. Cristalli, G.; Camaioni, E.; Costanzi, S.; Vittori, S.; Volpini, R.; Klotz, K.-N. *Drug Dev. Res.* **1998**, *45*, 176–181.
5. Volpini, R.; Costanzi, S.; Lambertucci, C.; Vittori, S.; Kachler, S.; Klotz, K.-N.; Cristalli, G. Presented at “Purines 2000: Biochemical, pharmacological and clinical perspectives” Abstract reported on *Special Issue Drug Dev. Res.* **2000**, *50*, 66 (072).
6. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, B.; Kull, B.; Fredholm, B. B.; Lohse, M. *J. Naunyn-Schmiedeberg's Arch. Pharmacol.* **1998**, *357*, 1–9.
7. van Tilburg, E. W.; von Frijtag Drabbe Künzel, J. K.; de Groote, M.; Vollinga, R. C.; Lorenzen, A.; IJzerman, A. P. *J. Med. Chem.* **1999**, *42*, 1393–1400.
8. Matsuda, A.; Shinozaki, M.; Yamaguchi, T.; Homma, H.; Nomoto, R.; Miyasaka, T.; Watanabe, Y.; Abiru, T. *J. Med. Chem.* **1992**, *35*, 241–252.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002509>